The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | The challenges of using kinase inhibitors for AML treatment
Using kinase inhibitors, such as midostaurin, to treat acute myeloid leukemia typically only produces a partial response. Mark Levis, MD, PhD, from The Johns Hopkins Hospital, Baltimore, MD, discusses why this is the case at the International Conference on Acute Myeloid Leukemia 2017 in Estoril, Portugal by the European School of Hematology (ESH). Dr Levis also highlights the challenges that current clinical trials of these inhibitors are trying to address.
